Cargando…
Portal hypertension and hepatocellular carcinoma: Navigating uncharted waters
Autores principales: | Sidali, Sabrina, Nault, Jean‐Charles |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8830280/ https://www.ncbi.nlm.nih.gov/pubmed/34997990 http://dx.doi.org/10.1002/ueg2.12193 |
Ejemplares similares
-
New concepts in the treatment of hepatocellular carcinoma
por: Sidali, Sabrina, et al.
Publicado: (2022) -
Prevalence and clinical significance of clinically evident portal hypertension in patients with hepatocellular carcinoma undergoing transarterial chemoembolization
por: Müller, Lukas, et al.
Publicado: (2021) -
Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma
por: Sanoff, Hanna K., et al.
Publicado: (2016) -
Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Opportunities and Challenges
por: Liu, Xiufeng, et al.
Publicado: (2019) -
Development of a Multivariate Prognostic Model for Lenvatinib Treatment in Hepatocellular Carcinoma
por: Li, Xiaomi, et al.
Publicado: (2023)